You just read:

Arkuda Therapeutics Closes $44M Series A Financing to Advance Novel Medicines Targeting Progranulin and Lysosomal Biology to Treat Neurodegenerative Diseases

News provided by

Arkuda Therapeutics

Nov 07, 2019, 05:00 ET